Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialResearch in context

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialResearch in context

Summary: Background: There is a significant association between low vitamin D levels at diagnosis of indolent B-cell lymphomas and inferior overall survival (OS). To determine whether supplemental vitamin D improves event-free survival (EFS) in these patients, we conducted a comparative double-blin...

Full description

Bibliographic Details
Main Authors: Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John G. Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:EClinicalMedicine
Subjects:
Lymphoma
Vitamin D
Cholecalciferol
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024005388

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024005388

Similar Items